More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments (CROSBI ID 290807)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Kandolf Sekulovic, L. ; Peris, K. ; Hauschild, A. ; Stratigos, A. ; Grob, J.-J. ; Nathan, P. ; Dummer, R. ; Forsea, A.-M. ; Hoeller, C. ; Gogas, H. ; Demidov, L. ; Lebbe, C. ; Blank, C. ; Olah, J. ; Bastholt, L. ; Herceg, Davorin ; Neyns, B. ; Vieira, R. ; Hansson, J. ; Rutkowski, P. ; Krajsova, I. ; Bylaite-Bucinskiene, M. ; Zalaudek, I. ; Marić- Brozić, Jasmina ; Babovic, N. ; Banjin, M. ; Putnik, K. ; Weinlich, G. ; Todorovic, V. ; Kirov, K. ; Ocvirk, J. ; Zhukavets, A. ; Kukushkina, M. ; De La Cruz Merino, L. ; Ymeri, A. ; Risteski, M. ; Garbe, C.
engleski
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF).
access ; innovative medicines ; metastatic melanoma ; treatment ; immunooncologytargeted therapyhealth expenditure per capita ; human development index
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
75
2017.
313-322
objavljeno
0959-8049
1879-0852
10.1016/j.ejca.2017.01.012
Povezanost rada
Kliničke medicinske znanosti
